Frankfurt - Delayed Quote EUR

Vaxart, Inc. (NB11.F)

0.3048

+0.0066

+(2.21%)

At close: April 17 at 7:01:27 PM GMT+2

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing v

GlobeNewswire yesterday

VXRT
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 shares and restricted stock unit awards covering 97,500 shares, and (ii) Laurie Hastings, our recently-app

GlobeNewswire 21 days ago

VXRT
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Vaxart ( NASDAQ:VXRT ) Full Year 2024 Results Key Financial Results Revenue: US$28.7m (up 289% from FY 2023). Net loss...

Simply Wall St. 26 days ago

VXRT
Q4 2024 Vaxart Inc Earnings Call

Q4 2024 Vaxart Inc Earnings Call

Thomson Reuters StreetEvents 27 days ago

VXRT
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...

Vaxart Inc (VXRT) reports significant revenue growth and strategic initiatives to extend cash runway, despite facing hurdles with BARDA-funded projects.

GuruFocus.com 28 days ago

VXRT
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 28 days ago

VXRT
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSW

GlobeNewswire 28 days ago

VXRT
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click here

GlobeNewswire last month

VXRT
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. “We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improv

GlobeNewswire last month

VXRT
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administrationSOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults (55-80 years) (NCT04854746) have been published in

GlobeNewswire last month

VXRT
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced the appointment of Kevin Finney to the Company’s Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member

GlobeNewswire 2 months ago

VXRT
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Norovirus program to proceed with Phase 1 study following scientific advisory board and FDA feedback; Trial to initiate the first half of 2025 with topline data expected as early as mid-2025 New avian influenza vaccine candidate being tested in preclinical studies SOUTH SAN FRANCISCO, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire 3 months ago

VXRT
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the trial to enrollment of 10,000 participants, upon favorable review from the U.S. Food and Drug Administration (FDA) and upon Biomedical Advanced Research and Development Authority (BARDA) approval SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced

GlobeNewswire 3 months ago

VXRT
Vaxart project agreement change ups funding for oral COVID vaccine candidate

In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study evaluating the Company’s oral pill XBB C

TipRanks 3 months ago

VXRT
Top Midday Gainers

Vaxart (VXRT) said on Friday it secured a $4.6 million increase in funding under a project agreement

PREMIUM
MT Newswires 3 months ago

GDYN

VXRT

AMED
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart’s COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. “We are pleased to complete the enrollment of the sen

GlobeNewswire 4 months ago

VXRT
Vaxart Third Quarter 2024 Earnings: Beats Expectations

Vaxart ( NASDAQ:VXRT ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.93m (up 135% from 3Q 2023). Net...

Simply Wall St. 4 months ago

VXRT
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...

Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue.

GuruFocus.com 5 months ago

VXRT
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

VXRT
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2024. “Our successful initiation of sentinel cohort dosing is a testament t

GlobeNewswire 5 months ago

VXRT

Performance Overview

Return	NB11.F	S&P 500 (^GSPC)
YTD	-54.84%	-10.18%
1-Year	-63.39%	+5.19%
3-Year	-93.27%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vaxart, Inc. (NB11.F)

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Q4 2024 Vaxart Inc Earnings Call

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart project agreement change ups funding for oral COVID vaccine candidate

Top Midday Gainers

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart Third Quarter 2024 Earnings: Beats Expectations

Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Performance Overview